Mannheimer Swartling advising the Board of Meda on Mylan’s recommended bid
Mylan, a leading global pharmaceutical company whose shares are traded on NASDAQ Global Select Market and the Tel Aviv Stock Exchange, has announced a recommended bid for Meda. Meda is a leading international specialty pharma company. Meda’s products are sold in more than 150 countries worldwide and the company is represented by its own organization in over 60 countries. The Meda share is listed under Large Cap on Nasdaq Stockholm. Meda’s net sales amounted to more than SEK 19 billion in 2015.
At announcement, the total value of the bid, including Meda net debt, is approximately SEK 83.6 billion.
Mannheimer Swartling are advising the Board of Meda. The firm’s team includes Eva Hägg, Patrik Marcelius, Magnus Olsson, Therese Lundgren, Stephanie Salehian, Johan Carle and Sofia Thelin.